PremiumThe FlyBiotech Alert: Searches spiking for these stocks today Strategic Divestment and Ambitious Targets Support Coherus Biosciences’ Buy Rating Positive Outlook for Coherus Biosciences: Buy Rating Backed by Strong Growth and Strategic Milestones PremiumCompany AnnouncementsCoherus Biosciences Board Member Stolper Steps Down Coherus Biosciences price target lowered to $1.05 from $1.50 at UBS Coherus Biosciences CCO Resigns After UDENYCA Divestiture PremiumThe FlyBiotech Alert: Searches spiking for these stocks today Coherus BioSciences’ Earnings Call: Growth and Challenges Coherus Biosciences: Strategic Divestment and Pipeline Focus Justify Buy Rating